share_log

Biora Therapeutics | SCHEDULE 13G: Others

Biora Therapeutics | SCHEDULE 13G: Others

Biora Therapeutics | SCHEDULE 13G：其他
SEC announcement ·  03/20 18:33
Moomoo AI 已提取核心信息
On March 12, 2024, Biora Therapeutics, Inc. was the subject of a Schedule 13G filing with the SEC, indicating a significant acquisition of shares by several entities and individuals. Context Capital Management, LLC, along with Michael S. Rosen, William D. Fertig, Charles E. Carnegie, and Context Partners Master Fund, L.P., reported shared voting and dispositive power over 2,989,698 shares of Biora Therapeutics' common stock, representing 0.9% of the class. The filing clarified that these parties are not forming a group and each disclaims beneficial ownership of the securities except to the extent of their pecuniary interest. The shares in question are issuable upon conversion of Convertible Senior Notes due 2028, subject to a 9.9% ownership limitation. The reported percentage ownership is based on 27,209,277 shares of Biora Therapeutics' common stock outstanding as of December 20, 2023. The filing was completed on March 20, 2024, with all parties certifying that the acquisition of shares is in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
On March 12, 2024, Biora Therapeutics, Inc. was the subject of a Schedule 13G filing with the SEC, indicating a significant acquisition of shares by several entities and individuals. Context Capital Management, LLC, along with Michael S. Rosen, William D. Fertig, Charles E. Carnegie, and Context Partners Master Fund, L.P., reported shared voting and dispositive power over 2,989,698 shares of Biora Therapeutics' common stock, representing 0.9% of the class. The filing clarified that these parties are not forming a group and each disclaims beneficial ownership of the securities except to the extent of their pecuniary interest. The shares in question are issuable upon conversion of Convertible Senior Notes due 2028, subject to a 9.9% ownership limitation. The reported percentage ownership is based on 27,209,277 shares of Biora Therapeutics' common stock outstanding as of December 20, 2023. The filing was completed on March 20, 2024, with all parties certifying that the acquisition of shares is in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
2024年3月12日，Biora Therapeutics, Inc.成为向美国证券交易委员会提交的附表13G文件的主体，这表明多个实体和个人对股票进行了重大收购。Context Capital Management, LLC以及迈克尔·罗森、威廉·费蒂格、查尔斯·卡内基和Context Partners万事达基金有限责任公司报告了对占该类别0.9％的Biora Therapeutics普通股的2,989,698股共享投票权和处置权。该文件澄清说，这些当事方没有组成一个团体，除非其金钱利益，否则均否认对证券的实益所有权。有关股票可在转换2028年到期的可转换优先票据后发行，但所有权限制为9.9％。报告的所有权百分比基于截至2023年12月20日的Biora Therapeutics已发行普通股的27,209,277股。该文件已于2024年3月20日完成，所有各方均证明收购股票是在正常业务过程中进行的，不是为了改变或影响发行人的控制权。
2024年3月12日，Biora Therapeutics, Inc.成为向美国证券交易委员会提交的附表13G文件的主体，这表明多个实体和个人对股票进行了重大收购。Context Capital Management, LLC以及迈克尔·罗森、威廉·费蒂格、查尔斯·卡内基和Context Partners万事达基金有限责任公司报告了对占该类别0.9％的Biora Therapeutics普通股的2,989,698股共享投票权和处置权。该文件澄清说，这些当事方没有组成一个团体，除非其金钱利益，否则均否认对证券的实益所有权。有关股票可在转换2028年到期的可转换优先票据后发行，但所有权限制为9.9％。报告的所有权百分比基于截至2023年12月20日的Biora Therapeutics已发行普通股的27,209,277股。该文件已于2024年3月20日完成，所有各方均证明收购股票是在正常业务过程中进行的，不是为了改变或影响发行人的控制权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息